logo
Twitter
Discord
Email
logo
Phreesia, Inc.

Phreesia, Inc.

NYSE•PHR
CEO: Mr. Chaim Indig
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2019-07-18
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.
Contact Information
1521 Concord Pike, Suite 301 PMB 221, Wilmington, DE, 19803, United States
888-654-7473
www.phreesia.com
Market Cap
$1.04B
P/E (TTM)
-190.7
35.7
Dividend Yield
--
52W High
$32.76
52W Low
$15.41
52W Range
11%
Rank61Top 80.3%
2.4
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025

Financial Dashboard

Q3 2026 Data

Revenue

$120.33M+12.67%
4-Quarter Trend

EPS

$0.08-88.40%
4-Quarter Trend

FCF

$12.20M+135.94%
4-Quarter Trend

2026 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Total revenue reached $120.3M for the quarter, marking a 13% increase from $106.8M last year.
Profitability Turnaround Achieved Quarterly net income was $4.3M, reversing the $14.4M net loss reported in the prior year period.
Adjusted EBITDA Surges Nine-month Adjusted EBITDA grew substantially to $72.1M, up from $20.4M in the comparable prior period.
Cash Flow Strengthens Free cash flow for the quarter was $8.8M, significantly higher than $1.6M generated in the prior year.

Risk Factors

Competition Pressures Margins Highly competitive industry requires effective competition against EHR/PM systems; results may be harmed.
Client Retention Uncertainty Reliance on existing clients; contracts may not renew or may renew at lower fee levels impacting revenue.
Cybersecurity and Data Risks Collecting sensitive patient data exposes the company to cyber-attacks, legal penalties, and reputational damage.
Growth Management Challenges Variable sales cycles and implementation delays risk revenue recognition timing and future operating fluctuations.

Outlook

AccessOne Integration Focus Management expects to integrate AccessOne acquisition, realizing anticipated operational synergies and benefits post-closing.
Financing Strategy Evolving Ability to satisfy $110M Bridge Loan maturity or secure favorable long-term alternative financing remains key.
Sustaining Growth Strategies Anticipated growth relies on effectively managing integration efforts and expanding client base organically and via M&A.
Target Market Determination Future success depends on ability to accurately determine target market size and achieve forecasted growth rates.

Peer Comparison

Revenue (TTM)

Teladoc Health, Inc.TDOC
$2.53B
-2.4%
Clover Health Investments, Corp.CLOV
$1.77B
+14.8%
Omnicell, Inc.OMCL
$1.18B
+10.7%

Gross Margin (Latest Quarter)

Phreesia, Inc.PHR
102.6%
+34.9pp
BioCryst Pharmaceuticals, Inc.BCRX
98.4%
+1.2pp
GoodRx Holdings, Inc.GDRX
93.2%
-0.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TXG$2.38B-31.8-10.3%8.5%
OMCL$2.18B109.41.6%10.0%
BCRX$1.60B-181.52.0%153.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.1%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Mar 10, 2026
|
EPS:-
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2026

    Period End: Oct 31, 2025|Filed: Dec 9, 2025|
    Revenue: $120.33M+12.7%
    |
    EPS: $0.08-88.4%
    Beat
  • Form 10-Q - Q2 2026

    Period End: Jul 31, 2025|Filed: Sep 5, 2025|
    Revenue: $117.26M+14.8%
    |
    EPS: $0.01-103.5%
    Beat
  • Form 10-Q - Q1 2026

    Period End: Apr 30, 2025|Filed: May 28, 2025|
    Revenue: $115.94M+14.5%
    |
    EPS: $-0.07-81.0%
    Beat
  • Form 10-K - FY 2025

    Period End: Jan 31, 2025|Filed: Mar 13, 2025|
    Revenue: $419.81M+17.8%
    |
    EPS: $-1.02+59.4%
    Miss
  • Form 10-Q - Q3 2025

    Period End: Oct 31, 2024|Filed: Dec 9, 2024|
    Revenue: $106.80M+16.6%
    |
    EPS: $0.65-212.1%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jul 31, 2024|Filed: Sep 5, 2024|
    Revenue: $102.12M+19.0%
    |
    EPS: $-0.31-54.4%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Apr 30, 2024|Filed: May 31, 2024|
    Revenue: $101.22M+20.7%
    |
    EPS: $-0.35-50.0%
    Beat
  • Form 10-K - FY 2024

    Period End: Jan 31, 2024|Filed: Mar 15, 2024|
    Revenue: $356.30M+26.8%
    |
    EPS: $-2.51+25.3%
    Miss